Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

First-in-Human Phase I Dose Escalation and Expansion Study Evaluating the Fc Optimized FLT3 Antibody Flysyn in Acute Myeloid Leukemia Patients with Minimal Residual Disease

Jonas S. Heitmann, MD, Daniela Dörfel, MD, Sabine Kayser, MD, Michael Heuser, Felicitas Thol, Silke Kapp-Schwoerer, MD, Wolfgang Bethge, MD, Ludger Grosse-Hovest, Martin Steiner, Melanie Märklin, PhD, Juliane S. Walz, MD, Richard F. Schlenk, Gundram Jung, MD, Helmut R. Salih

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-139493

Published: 2020

Journal Articles

Interim Results of a First in Man Study with the Fc-Optimized FLT3 Antibody Flysyn for Treatment of Acute Myeloid Leukemia with Minimal Residual Disease

Sabine Kayser, MD, Jonas S. Heitmann, MD, Daniela Dörfel, MD, Felicitas Thol, MD, Michael Heuser, MD, Melanie Märklin, PhD, Carsten Müller-Tidow, MD, Martin Steiner, Ludger Grosse-Hovest, Gundram Jung, MD, Richard F. Schlenk, MD, Helmut R. Salih, MD

Blood (2019) 134 (Supplement_1): 3928.

https://doi.org/10.1182/blood-2019-125327

Published: 2019

Journal Articles

Targeting the FMS-like Tyrosin Kinase 3 with the Unicar System: Preclinical Comparison of Murine and Humanized Single-Chain Variable Fragment-Based Targeting Modules

Frederick Fasslrinner, MD, Claudia Arndt, PhD, Anja Feldmann, PhD, Stefanie Koristka, PhD, Liliana Raquel Loureiro, PhD, Marc Schmitz, MD, Gundram Jung, MD, Martin Bornhaeuser, MD, Michael Bachmann, MD

Blood (2019) 134 (Supplement_1): 5614.

https://doi.org/10.1182/blood-2019-124279

Published: 2019

Journal Articles

Development and Preclinical Characterization of an Fc-Optimized CD133 Antibody for Induction of NK Cell Reactivity Against Myeloid Leukemia

Samuel Koerner, Julia Leibold, Ludger Grosse-Hovest, PhD, Hans-Joerg Buehring, PhD, Gundram Jung, MD, Lothar Kanz, MD, Helmut R. Salih, MD

Blood (2014) 124 (21): 2309.

https://doi.org/10.1182/blood.V124.21.2309.2309

Published: 2014

Journal Articles

An Fc-Engineered CD133 Antibody for Induction of NK Cell Reactivity Against Cancer Cells

Kathrin Rothfelder, Julia Leibold, Ludger Grosse-Hovest, PhD, Hans-Joerg Buehring, PhD, Gundram Jung, MD, Lothar Kanz, MD, Helmut R Salih, MD

Blood (2014) 124 (21): 2739.

https://doi.org/10.1182/blood.V124.21.2739.2739

Published: 2014

Journal Articles

Elimination Of Minimal Residual Disease (MRD) In AML Patients With a Novel Fc-Optimized FLT3 Antibody (4G8-SDIEM)

Helmut R. Salih, MD, Martin Hofmann, Ludger Grosse-Hovest, PhD, Tina Nuebling, PhD, Maximilian Bamberg, Steffen Aulwurm, PhD, Hans-Joerg Buehring, PHD, Wolfgang A. Bethge, MD, Lothar Kanz, MD, Gundram Jung, MD

Blood (2013) 122 (21): 1454.

https://doi.org/10.1182/blood.V122.21.1454.1454

Published: 2013

Journal Articles

From Bedside To Bench: Molecular Benchmarking Of An Fc-Optimized CD19 Antibody Used In Treatment Of Relapsed and Refractory Pediatric B-Lineage Acute Lymphoblastic Leukemia

Ursula J.E. Seidel, Ludger Grosse-Hovest, PhD, Patrick Schlegel, MD, Martin Hofmann, Friedhelm R. Schuster, MD, Kai-Erik Witte, Steffen Aulwurm, PhD, Rouwen Teltschik, Elwira Pyz, PhD, Hans-Georg Rammensee, Gundram Jung, MD, Rupert Handgretinger, Prof., Peter Lang, MD

Blood (2013) 122 (21): 3905.

https://doi.org/10.1182/blood.V122.21.3905.3905

Published: 2013

Journal Articles

The Role of OX40 and Its Ligand in Acute Myeloid Leukemia: Expression, Function and Modulation of NK Cell Anti-Leukemia Reactivity

Carla E Schumacher, Tina Nuebling, PhD, Martin Hofmann, Benjamin J Schmiedel, PhD, Lothar Kanz, MD, Gundram Jung, MD, Helmut R Salih, MD

Blood (2012) 120 (21): 3548.

https://doi.org/10.1182/blood.V120.21.3548.3548

Published: 2012

Journal Articles

Use of a Fc-Optimized CD19 Antibody for Treatment of MRD in Pediatric Patients with B-Lineage Acute Lymphoblastic Leukemia

Peter Lang, MD, Heiko-Manuel Teltschik, MD, Patrick Schlegel, MD, Ursula Seidel, Ludger Grosse-Hovest, PhD, Steffen Aulwurm, PhD, Martin Hofmann, Rouwen Teltschik, Kai Witte, MD, Hans-Georg Rammensee, Prof., Gundram Jung, MD, Rupert Handgretinger, MD

Blood (2012) 120 (21): 581.

https://doi.org/10.1182/blood.V120.21.581.581

Published: 2012

Journal Articles

Transfer of MHC Class I by Coating Platelets Enables Tumor Cells to Evade NK Cell Immune Surveillance by Conferring a “Pseudo Self” Phenotype

Theresa Placke, Hans-Georg Kopp, MD, Martin Schaller, MD, Gundram Jung, MD, Lothar Kanz, MD, Helmut R. Salih, MD

Blood (2010) 116 (21): 583.

https://doi.org/10.1182/blood.V116.21.583.583

Published: 2010

Journal Articles

Induction of Localized TNF Activity Against Tumors Using Bispecific Antibodies.

Matthias Krusch, Tanja Herrmann, Lothar Kanz, MD, Gundram Jung, MD, Helmut R. Salih, MD

Blood (2005) 106 (11): 2213.

https://doi.org/10.1182/blood.V106.11.2213.2213

Published: 2005

NARROW

First-in-Human Phase I Dose Escalation and Expansion Study Evaluating the Fc Optimized FLT3 Antibody Flysyn in Acute Myeloid Leukemia Patients with Minimal Residual Disease

Interim Results of a First in Man Study with the Fc-Optimized FLT3 Antibody Flysyn for Treatment of Acute Myeloid Leukemia with Minimal Residual Disease

Targeting the FMS-like Tyrosin Kinase 3 with the Unicar System: Preclinical Comparison of Murine and Humanized Single-Chain Variable Fragment-Based Targeting Modules

Development and Preclinical Characterization of an Fc-Optimized CD133 Antibody for Induction of NK Cell Reactivity Against Myeloid Leukemia

An Fc-Engineered CD133 Antibody for Induction of NK Cell Reactivity Against Cancer Cells

Elimination Of Minimal Residual Disease (MRD) In AML Patients With a Novel Fc-Optimized FLT3 Antibody (4G8-SDIEM)

From Bedside To Bench: Molecular Benchmarking Of An Fc-Optimized CD19 Antibody Used In Treatment Of Relapsed and Refractory Pediatric B-Lineage Acute Lymphoblastic Leukemia

The Role of OX40 and Its Ligand in Acute Myeloid Leukemia: Expression, Function and Modulation of NK Cell Anti-Leukemia Reactivity

Use of a Fc-Optimized CD19 Antibody for Treatment of MRD in Pediatric Patients with B-Lineage Acute Lymphoblastic Leukemia

Transfer of MHC Class I by Coating Platelets Enables Tumor Cells to Evade NK Cell Immune Surveillance by Conferring a “Pseudo Self” Phenotype

Induction of Localized TNF Activity Against Tumors Using Bispecific Antibodies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only